Remibrutinib
Medication used to treat chronic spontaneous urticaria
From Wikipedia, the free encyclopedia
Remibrutinib, sold under the brand name Rhapsido, is a medication used for the treatment of chronic spontaneous urticaria.[1] Remibrutinib is an oral, small molecule kinase inhibitor that inhibits Bruton's tyrosine kinase.[1] It is taken by mouth.[1]
| |
| Clinical data | |
|---|---|
| Trade names | Rhapsido |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a625116 |
| License data |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C27H27F2N5O3 |
| Molar mass | 507.542 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Remibrutinib was approved for medical use in the United States in September 2025,[4] and in the European Union in April 2026.[2][3] The US Food and Drug Administration considers it to be a first-in-class medication.[5][6]
Medical uses
Remibrutinib is indicated for the treatment of chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatment.[1][2]
Side effects
Common side effects include upper respiratory tract infections, headache, nasopharyngitis, and mild gastrointestinal symptoms such as diarrhea and nausea.[7][8]
Mechanism of action
Remibrutinib is a selective inhibitor of Bruton's tyrosine kinase, a key signaling protein found in mast cells and basophils that regulates their activation and degranulation via pathways involving the FcεRI and B-cell receptor. By irreversibly binding to Bruton's tyrosine kinase, remibrutinib blocks intracellular signaling required for the release of histamine and other inflammatory mediators, thereby reducing the immune cell-driven processes underlying chronic spontaneous urticaria. This mechanism enables suppression of urticaria symptoms upstream from antihistamines, and may also modulate autoimmune activity in some patients.[8]
Society and culture
Legal status
Remibrutinib was approved for medical use in the United States in September 2025.[9]
Names
Remibrutinib is the international nonproprietary name.[10]
Remibrutinib is sold under the brand name Rhapsido.[9]
